他汀类药物在结直肠癌防治中的研究进展

doi:10.3969/j.issn.1006-5725.2024.14.024

Abstract

Abstract:

Statins， known as hydroxymethylglutaryl coenzyme A reductase （HMG?CoA） inhibitors， are primarily used to lower blood lipids， preventing and treating cardiovascular diseases. Research indicates that statins exhibit multiple effects in the prevention and treatment of colorectal cancer. They function by inhibiting the MVA pathway， suppressing inflammation， enhancing cellular immunity， and influencing the gut microbiota， positively impacting the onset and progression of colorectal cancer. Clinical studies have additionally uncovered that statin drugs can augment the effectiveness of chemotherapy， immunotherapy， and adjuvant therapies， acting as both preventive and adjunctive measures for colorectal cancer. This article critically reviews the research progress on statins in colorectal cancer， aiming to establish a theoretical foundation for exploring innovative treatment options.

Key words: statins, colorectal cancer, prevention and treatment

CLC Number:

R972⁺.6

Mingxin TANG,Xiaolin WANG,Xuanfei. LI. Research progress of statins in the prevention and treatment of colorectal cancer[J]. The Journal of Practical Medicine, 2024, 40(14): 2041-2046.

Figures/Tables 1

References 51

1	SUNG H， FERLAY J， SIEGEL R L， et al. Global Cancer Statistics 2020： GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries ［J］. CA Cancer J Clin，2021，71（3）：209-249. doi:10.3322/caac.21660 doi: 10.3322/caac.21660
2	PEPPAS S， PIOVANI D， PEYRIN-BIROULET L， et al. Statins and inflammatory bowel disease： Where do we stand？［J］. Eur J Intern Med，2020，75：10-14. doi:10.1016/j.ejim.2020.02.017 doi: 10.1016/j.ejim.2020.02.017
3	KATONA B W， WEISS J M. Chemoprevention of Colorectal Cancer ［J］. Gastroenterology，2020，158（2）：368-388. doi:10.1053/j.gastro.2019.06.047 doi: 10.1053/j.gastro.2019.06.047
4	DENG C F， ZHU N， ZHAO T J， et al. Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential ［J］. Front Oncol，2022，12：803473. doi:10.3389/fonc.2022.803473 doi: 10.3389/fonc.2022.803473
5	HAYCOCK P C， BORGES M C， BURROWS K， et al. The association between genetically elevated polyunsaturated fatty acids and risk of cancer ［J］. EBioMedicine， 2023， 91： 104510-104510.
6	BETON-MYSUR K， BROŻEK-PŁUSKA B. A new modality for cholesterol impact tracking in colon cancer development - Raman imaging， fluorescence and AFM studies combined with chemometric analysis ［J］. Anal Methods，2023，15（39）：5199-5217. doi:10.1039/d3ay01040f doi: 10.1039/d3ay01040f
7	SHEN C J， CHAN R H， LIN B W， et al. Oleic acid-induced metastasis of KRAS/p53-mutant colorectal cancer relies on concurrent KRAS activation and IL-8 expression bypassing EGFR activation ［J］. Theranostics， 2023， 13（13）： 4650-4666. doi:10.7150/thno.85855 doi: 10.7150/thno.85855
8	JUAREZ D， FRUMAN D A. Targeting the Mevalonate Pathway in Cancer ［J］. Trends Cancer， 2021，7（6）： 525-540. doi:10.1016/j.trecan.2020.11.008 doi: 10.1016/j.trecan.2020.11.008
9	FERREIRA A， PEREIRA F， REIS C， et al. Crucial Role of Oncogenic KRAS Mutations in Apoptosis and Autophagy Regulation： Therapeutic Implications ［J］. Cells， 2022， 11（14）： 2183. doi:10.3390/cells11142183 doi: 10.3390/cells11142183
10	GALES L， FORSEA L， MITREA D， et al. Antidiabetics， Anthelmintics， Statins， and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy ［J］. Medicina （Kaunas）， 2022， 58（9）： 1239. doi:10.3390/medicina58091239 doi: 10.3390/medicina58091239
11	PAN Q， ZHONG S， WANG H， et al. The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability ［J］. Mol Cell， 2021，81（13）： 2736-2751.e2738. doi:10.1016/j.molcel.2021.04.009 doi: 10.1016/j.molcel.2021.04.009
12	XIAO Y， LIU Q， PENG N， et al. Lovastatin Inhibits RhoA to Suppress Canonical Wnt/β-Catenin Signaling and Alternative Wnt-YAP/TAZ Signaling in Colon Cancer ［J］. Cell Transplant， 2022， 31： 9636897221075749. doi:10.1177/09636897221075749 doi: 10.1177/09636897221075749
13	WANG Y N， RUAN D Y， WANG Z X， et al. Targeting the cholesterol-RORα/γ axis inhibits colorectal cancer progression through degrading c-myc ［J］. Oncogene，2022，41（49）： 5266-5278. doi:10.1038/s41388-022-02515-3 doi: 10.1038/s41388-022-02515-3
14	ZHANG K L， ZHU W W， WANG S H， et al. Organ-specific cholesterol metabolic aberration fuels liver metastasis of colorectal cancer ［J］. Theranostics， 2021，11（13）： 6560-6572. doi:10.7150/thno.55609 doi: 10.7150/thno.55609
15	ERKINANTTI S， HAUTAKOSKI A， SUND R， et al. The Association of Metformin， Other Antidiabetic Medications and Statins on the Prognosis of Rectal Cancer in Patients with Type 2 Diabetes： A Retrospective Cohort Study ［J］. Biomolecules， 2022， 12（9）： 1301. doi:10.3390/biom12091301 doi: 10.3390/biom12091301
16	SOLIMAN N A， KESHK W A， RIZK F H， et al. The possible ameliorative effect of simvastatin versus sulfasalazine on acetic acid induced ulcerative colitis in adult rats ［J］. Chem Biol Interact， 2019， 298： 57-65. doi:10.1016/j.cbi.2018.11.002 doi: 10.1016/j.cbi.2018.11.002
17	SELVIN T， BERGLUND M， LENHAMMAR L， et al. Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell death ［J］. BMC Cancer，2023，23（1）： 164. doi:10.1186/s12885-023-10645-4 doi: 10.1186/s12885-023-10645-4
18	HUANG X M， HUANG J J， DU J J， et al. Autophagy inhibitors increase the susceptibility of KRAS-mutant human colorectal cancer cells to a combined treatment of 2-deoxy-D-glucose and lovastatin ［J］. Acta Pharmacol Sin， 2021， 42（11）： 1875-1887. doi:10.1038/s41401-021-00612-9 doi: 10.1038/s41401-021-00612-9
19	CHEN M J， CHENG A C， LEE M F， et al. Simvastatin induces G（1） arrest by up-regulating GSK3β and down-regulating CDK4/cyclin D1 and CDK2/cyclin E1 in human primary colorectal cancer cells ［J］. J Cell Physiol， 2018， 233（6）： 4618-4625. doi:10.1002/jcp.26156 doi: 10.1002/jcp.26156
20	BIANCONI V， SAHEBKAR A， ATKIN S L， et al. The regulation and importance of monocyte chemoattractant protein-1 ［J］. Curr Opin Hematol， 2018， 25（1）： 44-51. doi:10.1097/moh.0000000000000389 doi: 10.1097/moh.0000000000000389
21	LIU J， HUANG X， LIU H， et al. Immune landscape and prognostic immune-related genes in KRAS-mutant colorectal cancer patients ［J］. J Transl Med， 2021，19（1）： 27. doi:10.1186/s12967-020-02638-9 doi: 10.1186/s12967-020-02638-9
22	NAM G H， KWON M， JUNG H， et al. Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer ［J］. J Immunother Cancer， 2021， 9（7）： e002474. doi:10.1136/jitc-2021-002474 doi: 10.1136/jitc-2021-002474
23	FRAZZI R. BIRC3 and BIRC5： multi-faceted inhibitors in cancer ［J］. Cell Biosci， 2021，11（1）： 8. doi:10.1186/s13578-020-00521-0 doi: 10.1186/s13578-020-00521-0
24	XIA Y， XIE Y， YU Z， et al. The Mevalonate Pathway Is a Druggable Target for Vaccine Adjuvant Discovery ［J］. Cell， 2018， 175（4）： 1059-1073.e1021. doi:10.1016/j.cell.2018.08.070 doi: 10.1016/j.cell.2018.08.070
25	WHITE M T， SEARS C L. The microbial landscape of colorectal cancer ［J］. Nat Rev Microbiol， 2023， 22（4）： 240-254. doi:10.1038/s41579-023-00973-4 doi: 10.1038/s41579-023-00973-4
26	HAN J X， TAO Z H， WANG J L， et al. Microbiota-derived tryptophan catabolites mediate the chemopreventive effects of statins on colorectal cancer ［J］. Nat Microbiol， 2023， 8（5）： 919-933. doi:10.1038/s41564-023-01363-5 doi: 10.1038/s41564-023-01363-5
27	CERVANTES-BARRAGAN L， CHAI J N， TIANERO M D， et al. Lactobacillus reuteri induces gut intraepithelial CD4（+）CD8αα（+） T cells ［J］. Science， 2017， 357（6353）： 806-810. doi:10.1126/science.aah5825 doi: 10.1126/science.aah5825
28	OKAMOTO K， NOZAWA H， EMOTO S， et al. Does statin suppress oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer？A single-center observational study ［J］. Support Care Cancer， 2023， 31（12）： 660. doi:10.1007/s00520-023-08134-2 doi: 10.1007/s00520-023-08134-2
29	黄锐，刘超，张艳桥. 辛伐他汀用于结直肠癌治疗的系统综述［J］. 实用肿瘤学杂志， 2021，35（4）： 365-369. doi:10.11904/j.issn.1002-3070.2021.04.013 doi: 10.11904/j.issn.1002-3070.2021.04.013
30	XIA J， HE S， DAI Q， et al. Atorvastatin calcium alleviates 5-fluorouracil-induced intestinal damage by inhibiting cellular senescence and significantly enhances its antitumor efficacy ［J］. Int Immunopharmacol， 2023， 121： 110465. doi:10.1016/j.intimp.2023.110620 doi: 10.1016/j.intimp.2023.110620
31	TSUBAKI M， TAKEDA T， MATSUDA T， et al. Statins enhances antitumor effect of oxaliplatin in KRAS-mutated colorectal cancer cells and inhibits oxaliplatin-induced neuropathy ［J］. Cancer Cell Int， 2023， 23（1）： 73. doi:10.1186/s12935-023-02884-z doi: 10.1186/s12935-023-02884-z
32	KIM Y， KIM T W， HAN S W， et al. A Single Arm， Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients ［J］. Cancer Res Treat， 2019， 51（3）： 1128-1134. doi:10.4143/crt.2018.379 doi: 10.4143/crt.2018.379
33	YUAN T， WU R， WANG W， et al. Synergistic antitumor activity of regorafenib and rosuvastatin in colorectal cancer ［J］. Front Pharmacol， 2023， 14： 1136114. doi:10.3389/fphar.2023.1136114 doi: 10.3389/fphar.2023.1136114
34	NI W， MO H， LIU Y， et al. Targeting cholesterol biosynthesis promotes anti-tumor immunity by inhibiting long noncoding RNA SNHG29-mediated YAP activation ［J］. Mol Ther， 2021， 29（10）： 2995-3010. doi:10.1016/j.ymthe.2021.05.012 doi: 10.1016/j.ymthe.2021.05.012
35	YANG Y， QI J， HU J， et al. Lovastatin/SN38 co-loaded liposomes amplified ICB therapeutic effect via remodeling the immunologically-cold colon tumor and synergized stimulation of cGAS-STING pathway ［J］. Cancer Lett， 2024， 588： 216765. doi:10.1016/j.canlet.2024.216765 doi: 10.1016/j.canlet.2024.216765
36	BAO H， ZHENG N， LI Z， et al. Synergistic Effect of Tangeretin and Atorvastatin for Colon Cancer Combination Therapy： Targeted Delivery of These Dual Drugs Using RGD Peptide Decorated Nanocarriers ［J］. Drug Des Devel Ther， 2020， 14： 3057-3068. doi:10.2147/dddt.s256636 doi: 10.2147/dddt.s256636
37	KARAGKOUNIS G， DEVECCHIO J， FERRANDON S， et al. Simvastatin enhances radiation sensitivity of colorectal cancer cells ［J］. Surg Endosc， 2018， 32（3）： 1533-1539. doi:10.1007/s00464-017-5841-1 doi: 10.1007/s00464-017-5841-1
38	CAPUTO F， SANTINI C， CASADEI-GARDINI A， et al. Statins increase pathological response in locally advanced rectal cancer treated with chemoradiation： a multicenter experience ［J］. Future Oncol， 2022， 18（24）： 2651-2659. doi:10.2217/fon-2021-1646 doi: 10.2217/fon-2021-1646
39	GASH K J， CHAMBERS A C， COTTON D E， et al. Potentiating the effects of radiotherapy in rectal cancer： the role of aspirin， statins and metformin as adjuncts to therapy ［J］. Br J Cancer， 2017， 117（2）： 210-219. doi:10.1038/bjc.2017.175 doi: 10.1038/bjc.2017.175
40	FONG W， TO K K W. Drug repurposing to overcome resistance to various therapies for colorectal cancer ［J］. Cell Mol Life Sci， 2019， 76（17）： 3383-3406. doi:10.1007/s00018-019-03134-0 doi: 10.1007/s00018-019-03134-0
41	OUAHOUD S， JACOBS R J， KODACH L L， et al. Statin use is associated with a reduced incidence of colorectal cancer expressing SMAD4 ［J］. Br J Cancer， 2022， 126（2）： 297-301. doi:10.1038/s41416-021-01604-6 doi: 10.1038/s41416-021-01604-6
42	MARRONE M T， MONDUL A M， PRIZMENT A E， et al. Lipid-Lowering Drug Use and Cancer Incidence and Mortality in the ARIC Study ［J］. JNCI Cancer Spectr， 2021， 5（5）： pkab080. doi:10.1093/jncics/pkab080 doi: 10.1093/jncics/pkab080
43	RODRÍGUEZ-MIGUEL A， FERNÁNDEZ-ANTÓN E， BARRE-IRA-HERNÁNDEZ D， et al. Statins and Colorectal Cancer Risk： A Population-Based Case-Control Study and Synthesis of the Epidemiological Evidence ［J］. J Clin Med， 2022， 11（6）： 1528. doi:10.3390/jcm11061528 doi: 10.3390/jcm11061528
44	SUN J， HALFVARSON J， BERGMAN D， et al. Statin use and risk of colorectal cancer in patients with inflammatory bowel disease ［J］. EClinicalMedicine， 2023， 63： 102182. doi:10.1016/j.eclinm.2023.102182 doi: 10.1016/j.eclinm.2023.102182
45	LI Y， HE X， DING Y， et al. Statin uses and mortality in colorectal cancer patients： An updated systematic review and meta-analysis ［J］. Cancer Med， 2019， 8（6）： 3305-3313. doi:10.1002/cam4.2151 doi: 10.1002/cam4.2151
46	POURLOTFI A， BASS G A， HULME R AHL， et al. Statin Use and Long-Term Mortality after Rectal Cancer Surgery ［J］. Cancers （Basel）， 2021， 13（17）： 4288. doi:10.3390/cancers13174288 doi: 10.3390/cancers13174288
47	POURLOTFI A， HULME R AHL， FORSSTEN M P， et al. Statin therapy and its association with long-term survival after colon cancer surgery ［J］. Surgery， 2022， 171（4）： 890-896. doi:10.1016/j.surg.2021.08.002 doi: 10.1016/j.surg.2021.08.002
48	ARAI J， SUZUKI N， NIIKURA R， et al. Chemoprevention for Colorectal Cancers： Are Chemopreventive Effects Different Between Left and Right Sided Colorectal Cancers？［J］. Dig Dis Sci， 2022， 67（11）： 5227-5238. doi:10.1007/s10620-022-07431-w doi: 10.1007/s10620-022-07431-w
49	ZHANG Y， WU K， CHAN A T， et al. Long-Term Statin Use， Total Cholesterol Level， and Risk of Colorectal Cancer： A Prospective Cohort Study ［J］. Am J Gastroenterol， 2022， 117（1）： 158-166. doi:10.14309/ajg.0000000000001543 doi: 10.14309/ajg.0000000000001543
50	JEONG G H， LEE K H， KIM J Y， et al. Statin and Cancer Mortality and Survival： An Umbrella Systematic Review and Meta-Analysis ［J］. J Clin Med， 2020， 9（2）： 326. doi:10.3390/jcm9020326 doi: 10.3390/jcm9020326
51	MIN Y， WEI X， LIU Z， et al. Assessing the role of lipid-lowering therapy on multi-cancer prevention： A mendelian randomization study ［J］. Front Pharmacol， 2023， 14： 1109580. doi:10.3389/fphar.2023.1109580 doi: 10.3389/fphar.2023.1109580

[1]	Yuxuan DING,Lining GUO,Jiayi SHEN,Lijun. WANG. Safety and efficacy of radiotherapy and PD⁃1/PD⁃L1 inhibitor + TKI for MSS/pMMR colorectal cancer with liver metastases [J]. The Journal of Practical Medicine, 2024, 40(9): 1293-1297.
[2]	Feng ZHANG,Hongying. JIANG. Progress in prevention and treatment of arteriovenous fistula dysfunction [J]. The Journal of Practical Medicine, 2024, 40(13): 1767-1770.
[3]	LI Xiaoping, ZHOU Hongjian, GAO Fangfang, LI Wei.. Tspan1 antagonizes oxaliplatin⁃induced apoptosis in colorectal cancer cells by inducing cellular autophagy [J]. The Journal of Practical Medicine, 2023, 39(9): 1072-1078.
[4]	HAO Jian, HAN Lei.. Diagnostic value of single and combined panel of serum exosomal microRNAs in colorectal cancer [J]. The Journal of Practical Medicine, 2023, 39(3): 364-373.
[5]	Fengshuai YANG,Dongda QIU,Yunquan YANG,Shuangxi GONG,Shilin CHEN,Xinyu. WANG. The effect of targeted regulation of miR⁃516a⁃5p by LncRNA SNHG16 on the proliferation， invasion， and migration ability of colorectal cancer cells [J]. The Journal of Practical Medicine, 2023, 39(20): 2591-2596.
[6]	Jianfeng ZHANG,Bin YU,Zhenya ZHANG,Guiying. WANG. Advances in the diagnosis and treatment of postoperative delirium in colorectal cancer [J]. The Journal of Practical Medicine, 2023, 39(20): 2687-2690.
[7]	XIAO Peng, LI Weijuan, MEI Jiazhuan, BAI Hua, LI Min, LIU Guiju, LI Ruijun.. Efficacy and safety of apatinib plus PD⁃1 blockades as subsequent line therapy for patients with advanced colorectal cancer [J]. The Journal of Practical Medicine, 2023, 39(2): 255-261.
[8]	Xiaoqin SU,Xi CHEN,Haihua FAN,Congfei JI,Tingting NI,Yang YU,Jia. CHEN. The clinical value of PD1 inhibitor combined with furoquantinib and TAS⁃102 posterior therapy for advanced colorectal cancer [J]. The Journal of Practical Medicine, 2023, 39(18): 2389-2394.
[9]	HU Lang, LIN Xiaoling, TANG Wenjun. . Efficacy and safety of fruquintinib alone and in combination with PD⁃1 inhibitors for postline treatment of advanced metastatic colon cancer [J]. The Journal of Practical Medicine, 2023, 39(15): 1966-1973.
[10]	LI Ningkang, MA Tao, MA Xu, ZHOU Xiaohong, YANG Lifeng, ZHANG Lei, WANG Yun. . The effects of quadratus lumborum block on inflammatory response and postoperative intestinal function recovery in patients undergoing laparoscopic colorectal cancer surgery [J]. The Journal of Practical Medicine, 2023, 39(14): 1769-1773.
[11]	YANG Jinlan, QU Tianyin, DAI Qing, MA Jingjing, YU Huangfei, LI Yajun. . Ferroptotic cell death in colorectal cancer regulated by SERT inhibition combined with erastin [J]. The Journal of Practical Medicine, 2023, 39(10): 1206-1211.
[12]	XIAO Guozhong, HE Qiulan, LIU Fang, CHEN Huaxian, WAN Xingyang, REN Donglin, LIN Hongcheng. . Effect of modified Sijunzi decoction on tumor microenvironment in patients with colorectal cancer chemo⁃ therapy based on single ⁃ cell sequencing [J]. The Journal of Practical Medicine, 2023, 39(10): 1296-1304.
[13]	ZENG Jiaxing, TIAN Jingjing, LU Wei, HUANG Rui, CHEN Junhao, ZHANG Lin, XIE Xueqing, ZHANG Yuanling, DING Jie.. Value of fecal miRNA as a biomarker in diagnosis and prognostic assessment of colorectal cancer [J]. The Journal of Practical Medicine, 2022, 38(8): 1027-1031.
[14]	LIANG Weijie, ZHANG Yaowei, WANG Yongjia, WENG Jiawen, ZHENG Yilin, DING Yi.. AIFM3 interferes the proliferation and migration of colorectal cancer cells by regulating STAT3 signaling pathway [J]. The Journal of Practical Medicine, 2022, 38(7): 821-827.
[15]	SIMA Xueqin, SU Yanting, ZENG Zhi. The relationship between KRAS and BRAF gene mutations and prognosis of colorectal cancer detected by next generation sequencing [J]. The Journal of Practical Medicine, 2022, 38(21): 2670-2675.

Research progress of statins in the prevention and treatment of colorectal cancer

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References 51

Related Articles 15

Recommended Articles

Metrics

Comments